

IMMUNOTHERAPY

IN EPITHELIAL OVARIAN CANCER


Presented by: Assoc.Prof.Tarinee Manchana

Head of Division of Gynecologic Oncology

Department of Obstetrics and Gynecology


Faculty of Medicine, Chulalongkorn University

Bangkok, Thailand



Tarinee Manchana

ROLE OF ICI IN OVARIAN CANCER



Tarinee Manchana

1.Hamanishi J, et al. JCO 2021;39:3671-81; 2. Monk BJ, et al. Lancet Oncol 2021;22:1275-89; 3. Pujade-Lauraine E, et al. Lancet Oncol 2021;22:1034-46; 4. Moore KN, et al. JCO 2021;39:1842-55; 5. Kurtz JE, et al. JCO 2023;41:4768-78; 6. Monk BJ, et al. Ann Oncol 2024;35:S1223-4; 7. Gonzalez-Martin A, et al. JCO 2024;42:4294-304; 8. Harter P, et al. Ann Oncol 2025;S0923-7534(25)06315-X; 9. Hardy-Bessard AC, et al. Ann Oncol 2025; 36:1503-13; 10. Vergote I, et al IJGC 2025;35:101704; 11. Frederik M, et al. JCO 2024;42(supp 17):LBA5501; 12. Colombo N, et al. Presented at ESMO Congress 2025.

NCCN GUIDELINES (2025)

Platinum Resistant Ovarian cancer (PROC)

1

Preferred regimens

Cytotoxic therapy

- Cyclophosphamide (oral)+BEV
- Docetaxel
- Etoposide (oral)
- Gemcitabine
- PLD+BEV
- Weekly Paclitaxel+BEV
- Topotecan+BEV

Targeted therapy

- Bevacizumab
- Mirvetuximab soravtasine (FR α \geq 75%)

2

Other regimens

Cytotoxic therapy

- Capecitabine, cyclophosphamide+Pem+BEV, doxorubicin, gem+BEV, ifosfamide, irinotecan, melphalan, oxaliplatin, paclitaxel, pemetrexed, sorafenib+topotecan, vinorelbine

Targeted therapy

- Pazopanil (cat2B), PARPi (cat3)

Hormone therapy

- Aromatase inhibitor, GnRH agonist, megestrol acetate, tamoxifen

3

Certain circumstances

Immunotherapy

- Dostarlimab (dMMR/MSI-H)
- Pembrolizumab (dMMR/MSI-H/TMB-H)

Targeted therapy

- Trastuzumab deruxtecan (HER-3 IHC3+ or 2+)
- Mirvetuximab soravtasine+BEV (FR α \geq 25%)

Sarinee Manthana

Promising treatments in PROC

Phase 3 positive results

Mirvetuximab soravtansine

FR α -directed ADC (DM4)
USFDA and EU approval for FR α -positive PROC
with 1-3 prior systemic therapies

- FORWARD ¹
- MIRASOL ²

Relacorilant +Nab-paclitaxel

Selective glucocorticoid receptor antagonists
Restore sensitivity to cytotoxic chemotherapy

- ROSELLA ³

Pembrolizumab + Weekly paclitaxel

- KEYNOTE-B96 ⁴

Promising treatments in PROOC

Phase 2 trial

ICIs+PARPi

- TOPACIO ¹ (pembro+niraparib)

ICIs + Mirvetuximab

- FORWARD II ³
(mirvetuximab+pembro)

ICIs+TKI

- LEAP-005 ²
(Pembrolizumab+Lenvatinib)

ICIs + Anti CTLA-4

- NRG-GY003 ⁴
(nivolumab+ipilimumab)
- BrUOG 354 ⁵
(nivolumab+ipilimumab)